Condition: Epithelial Ovarian Cancer · Sponsor: Institut Claudius Regaud
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive treatment (platinum based-chemotherapy) according to the standard practices. A prospective database and an associated biological collection will be performed during 5 years: * For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care. * Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study). Study participation of each patient will be 5 years.
This description comes directly from the study's public registry record.
Gwenaël FERRON · 05 31 15 53 55 · Ferron.Gwenael@iuct-oncopole.fr
Always discuss trial participation with your own doctor first.
| Institut Universitaire du Cancer de Toulouse - Oncopole | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03954171